BCL10 is not a major target for frequent loss of 1p in testicular germ cell tumors

被引:10
作者
Kakinuma, H
Habuchi, T
Ito, T
Mishina, M
Sato, K
Satoh, S
Akao, T
Ogawa, O
Kato, T
机构
[1] Akita Univ, Sch Med, Dept Urol, Akita 0108543, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 6068507, Japan
关键词
D O I
10.1016/S0165-4608(00)00405-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The deletion of chromosome Ip is one of the frequent genetic alterations found in testicular germ cell tumors (GCTs), suggesting the presence of a tumor suppressor gene. BCL10, which was identified as a gene altered in mucosa-associated lymphoid tissue lymphoma, has been mapped at 1p22. The gene has been reported to be mutated in a variety of human cancers. In this study, we investigated the allelic deletions on Ip and the mutation of BCL10 in 51 GCTs comprising 30 seminomas and 21 non-seminomatous germ cell tumors. Loss of heterozygosity (LOH) on 1p was tested using three microsatellite markers. The search for BCL10 mutations in each of the three exons was screened by a single-stranded conformation polymorphism (SSCP) analysis and samples with abnormal bandshifts were directly sequenced. LOH at at least one locus tested was found in 42% (21/49) of the tumors (43% of seminomas and 38% of NSGCTs). SSCP and direct sequence analyses revealed that there were single nucleotide polymorphisms at codon 5, 8, 162, and intron 1. However, there were no somatic mutations of BCL10 in the 51 tumors. In support of the previous studies, our results demonstrated that LOH on Ip is frequent in both seminomas and NSGCTs, indicating that there is an important tumor suppressor on IF in GCT. However. the results indicate that BCL10 is not a candidate target gene of the Ip deletion. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:134 / 138
页数:5
相关论文
共 27 条
[1]  
CHAGANTI RSK, 1999, COMPREHENSIVE TXB GE, P891
[2]  
Du MQ, 2000, BLOOD, V95, P3885
[3]   Lack of BCL10 mutations in germ cell tumors and B cell lymphomas [J].
Fakruddin, JM ;
Chaganti, RSK ;
Murty, VVVS .
CELL, 1999, 97 (06) :683-684
[4]   BCL10 is rarely mutated in human prostate carcinoma, small-cell lung cancer, head and neck tumours, renal carcinoma and sarcomas [J].
Gill, S ;
Broni, J ;
Jefferies, S ;
Osin, P ;
Kovacs, G ;
Maitland, NJ ;
Eeles, R ;
Edwards, SM ;
Dyer, MJS ;
Willis, TG ;
Cooper, CS .
BRITISH JOURNAL OF CANCER, 1999, 80 (10) :1565-1568
[5]   Screening for mutations of Bcl10 in leukaemia [J].
Grimwade, D ;
Du, MQ ;
Langabeer, S ;
Rogers, J ;
Solomon, E .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) :611-615
[6]  
HEIM S, 1989, ADV CANCER RES, V52, P1
[7]   Bcl10 is not a target for frequent mutation in human carcinomas [J].
Lambers, AR ;
Gumbs, C ;
Ali, S ;
Marks, JR ;
Iglehart, JD ;
Berchuck, A ;
Futreal, PA .
BRITISH JOURNAL OF CANCER, 1999, 80 (10) :1575-1576
[8]  
Lee SD, 1999, J MED VIROL, V59, P1, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt
[9]  
1::AID-JMV1&gt
[10]  
3.0.CO